Publicacions
El coneixement generat a IrsiCaixa es comparteix amb la comunitat científica a través de la publicació d’articles a revistes científiques d’alt impacte.
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial.
Initial antigen encounter determines robust T-cell immunity against SARS-CoV-2 BA.2.86 variant three years later.
Protocol for flow cytometry immunophenotyping of human antigen-specific T cells by activation-induced marker and Th1 cytokine detection.
Pathobiont-induced suppressive immune imprints thwart T cell vaccine responses.
Refinement of post-COVID condition core symptoms, subtypes, determinants, and health impacts: a cohort study integrating real-world data and patient-reported outcomes.
SARS-CoV-2 Infection Risk by Vaccine Doses and Prior Infections Over 24 Months: ProHEpiC-19 Longitudinal Study.
40 years fighting the human immunodeficiency virus (HIV), but still no definitive cure
Exploring potential associations between the human microbiota and reservoir of latent HIV.
Assessing advances in three decades of clinical antiretroviral therapy on the HIV-1 reservoir.
Assessing the Prognostic Value of Cytoplasmic and Stromal Caveolin-1 in Early Triple-Negative Breast Cancer Undergoing Neoadjuvant Chemotherapy.